We also sought to determine whether G-CSF mobilized EPCs in the context of attenuating delayed tPA-induced HT possibly via vascular repair, and if the therapeutic effects of single G-CSF treatments were sustained at longer post-stroke time points. This evidence concerns the gene CSF3 and hematocrit.